We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunotherapeutics in development for prostate cancer.
- Authors
Harzstark, Andrea L; Small, Eric J
- Abstract
Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive work has been done evaluating multiple immunotherapies for the treatment of prostate cancer. This review discusses clinical results for the most promising developments. These include cytokine-based therapy with GM-CSF; vaccines; antibody-based immunotherapies, including anti-cytotoxic T lymphocyte associated antigen 4 therapy and antibodies against additional targets; and dendritic cell-based immunotherapy.
- Publication
The oncologist, 2009, Vol 14, Issue 4, p391
- ISSN
1549-490X
- Publication type
Journal Article
- DOI
10.1634/theoncologist.2008-0240